Baird lowered the firm’s price target on Global Medical REIT (GMRE) to $9 from $10 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which were ahead due to NOI and guidance was unchanged.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMRE:
- Strategic Positioning and Strong Financial Performance Drive Buy Rating for Global Medical REIT
- Cautious Hold Rating on Global Medical REIT Amid Financial Strain and Strategic Uncertainty
- Global Medical REIT reports Q1 AFFO 22c, consensus 22c
- Global Medical REIT backs FY25 AFFO view 89c-93c, consensus 91c
- GMRE Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue